News & Publications

Inventprise Press Releases

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

•
January 2, 2024

New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation

•
November 10, 2022

Inventprise Inaugurates Manufacturing Facility for High-Capacity Supply of Pneumococcal Conjugate Vaccines

•
May 10, 2022

Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board

•
April 7, 2022

Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials

•
November 10, 2021

Inventprise in the News

Inventprise CEO Attends 2nd Global Forum on Childhood Pneumonia

•
April 27, 2023

Every Breath Counts: Pneumococcal Conjugate Vaccine Scorecard 2022

•
February 6, 2023

PATH: Inventprise’s Expanded-coverage Pneumococcal Vaccine Enters the Clinic

•
February 3, 2023

Precision Vaccinations: Pneumococcal Vaccines 2023

•
January 17, 2023

Gates Notes: A Promising New Vaccine to Protect Children from Their #1 Killer

•
September 6, 2022

Biospace: Gates Foundation Pours $90 Million into Promising New Pneumococcal Vaccine

•
November 11, 2021

GeekWire: Seattle-Area Startup Inventprise Gets Backing from Gates Foundation for Pneumonia Shot

•
November 10, 2021

Publications

Human Vaccines & Immunotherapies: Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production

•
August 22, 2022

Poster Presentation: Preclinical Results for a 25-Valent Penumococcal Conjugate Vaccine Using A Novel Linker Platform Technology – ISPPD-12 | June, 2022

•
June 22, 2022